Explore 3 Stock Ideas & Industry Insights Download Free Report

Company price
None GBX 0.00(0%)
Last update at 2026-10-28T03:30:16.858216Z
Market Cap
169.71M
P/E
61.50

Momentum Score

…

Animalcare Group plc develops, sells, and distributes licensed veterinary pharmaceuticals, and services for companion and production animals, and equine veterinary markets. The company has a collaboration with 272Bio Limited to develop and commercialize a novel biological treatment for a common equine skin condition, known as sweet itch. The company operates in Belgium, the Netherlands, the United Kingdom, Germany, Spain, Italy, Portugal, Asia, the Middle East, Africa, European Union, and internationally. Animalcare Group plc is based in York, the United Kingdom.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
205.76
Low
299.17
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
2.11%
Revenue TTM
81.07M
Revenue Per Share
1.24
Gross Profit TTM
44.95M
Debt / Equity
0.21
ROE
2.83%
Net Debt
12.29M
ROCE
4.52%
Diluted EPS TTM
0.04

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax 5.78M 3.28M 2.54M 0.94M 0.20M
Net income 32.22M 1.20M 1.97M -0.08M 0.23M
Selling general administrative 9.21M 10.01M 15.00M 14.48M 13.30M
Selling and marketing expenses 3.45M 3.18M 13.55M 12.28M 12.32M
Gross profit 34.06M 43.35M 40.66M 39.42M 36.56M
Reconciled depreciation 7.18M 7.71M 7.80M 8.40M 9.39M
Ebit 6.25M 4.12M 3.24M 1.99M 2.59M
Ebitda 13.43M 11.82M 12.07M 10.19M 11.98M
Depreciation and amortization 7.18M 7.71M 8.84M 8.20M 9.39M
Operating income 4.50M 4.41M 3.24M 1.99M 2.59M
Other operating expenses 69.73M 69.94M 67.22M 71.72M 67.83M
Interest expense 0.50M 0.69M 0.44M 0.45M 0.52M
Tax provision 0.97M 2.32M 0.58M 1.02M -0.04M
Interest income 0.00M 0.05M 0.01M 0.00M 0.01M
Net interest income -0.50M -0.91M -0.63M -0.61M -0.59M
Income tax expense 0.97M 2.19M 0.58M 1.02M -0.04M
Total revenue 74.23M 74.35M 71.62M 74.02M 70.49M
Total operating expenses 29.56M 38.94M 36.26M 37.12M 33.90M
Cost of revenue 40.16M 31.00M 30.96M 34.61M 33.94M
Total other income expense net 1.28M -1.13M -0.69M -1.04M -2.39M
Net income from continuing ops 4.82M 1.20M 1.97M -0.08M 0.23M
Net income applicable to common shares - - 1.97M -0.08M 0.23M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 158.81M 106.79M 118.24M 110.00M 124.44M
Intangible assets 16.60M 20.58M 25.28M 29.72M 37.81M
Other current assets 60.30M 0.29M 0.71M 1.20M 1.59M
Total liab 45.50M 28.90M 39.26M 31.20M 42.84M
Total stockholder equity 113.31M 77.89M 78.99M 78.80M 81.59M
Other current liab 5.04M 6.57M 5.93M 2.16M 3.20M
Common stock 13.79M 12.02M 12.02M 12.02M 12.01M
Capital stock 13.79M 12.02M 12.02M 12.02M 12.01M
Retained earnings -52.56M -12.78M -11.98M -11.68M -9.45M
Other liab - - 6.40M 6.51M 6.17M
Good will 39.36M 50.66M 50.85M 50.34M 50.99M
Other assets 0.00M -0.29M 3.64M 2.08M 2.27M
Cash 11.71M 4.64M 6.04M 5.63M 5.26M
Total current liabilities 20.61M 18.42M 22.27M 14.45M 19.38M
Current deferred revenue - 0.87M - 1.55M 3.24M
Net debt 12.29M 1.23M 5.40M 5.33M 13.62M
Short term debt 2.66M 0.91M 0.85M 0.72M 1.59M
Short long term debt 0.98M 0.00M - 0.00M 0.64M
Short long term debt total 24.01M 5.88M 11.44M 10.96M 18.88M
Other stockholder equity 152.08M 76.04M 78.94M 78.46M 79.03M
Property plant equipment - - 3.37M 2.28M 2.06M
Total current assets 97.96M 29.41M 33.79M 24.30M 29.79M
Net tangible assets - - 2.85M -1.26M -7.21M
Net receivables 14.20M 14.42M 13.57M 7.13M 10.14M
Long term debt 19.75M 2.93M 8.43M 9.24M 16.43M
Inventory 11.75M 10.06M 13.47M 10.33M 12.80M
Accounts payable 12.91M 10.81M 15.50M 10.02M 11.35M
Accumulated other comprehensive income 2.09M 2.62M - - -1.89M
Common stock total equity - - - - 12.01M
Non currrent assets other -0.00M 0.29M 1.38M 0.02M 0.05M
Non current assets total 60.85M 77.67M 84.45M 85.71M 94.64M
Capital lease obligations 2.44M 2.94M 3.01M 1.72M 1.81M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -33.86M -2.86M -3.12M -0.29M -0.59M
Change to liabilities - - 6.71M -2.70M 0.88M
Total cashflows from investing activities -34.85M -2.86M -3.12M -2.96M -2.91M
Net borrowings 17.81M -5.25M -2.32M -7.98M -7.09M
Total cash from financing activities 32.53M -8.95M -5.70M -10.96M -8.86M
Net income 4.82M 1.20M 2.54M 0.94M 0.20M
Change in cash 7.07M -1.39M 0.40M 0.37M -0.90M
Begin period cash flow 4.64M 6.04M 5.63M 5.26M 6.17M
End period cash flow 11.71M 4.64M 6.04M 5.63M 5.26M
Total cash from operating activities 11.93M 10.28M 9.43M 14.02M 11.12M
Issuance of capital stock 20.05M 0.00M 0.00M 0.08M -
Depreciation 7.18M 7.71M 7.80M 8.40M 9.39M
Other cashflows from investing activities -0.93M -2.19M - - -0.47M
Dividends paid 3.02M 2.64M 2.64M 2.40M 1.20M
Change to inventory -3.46M 2.26M -2.73M 1.36M -1.61M
Change to account receivables 1.01M -0.32M -5.88M 3.54M 0.64M
Sale purchase of stock - - - 0.05M -
Other cashflows from financing activities -1.36M -1.05M -1.73M -0.21M -1.65M
Change to netincome - - 1.56M 3.50M 1.58M
Capital expenditures 0.21M 2.55M 2.95M 3.21M 2.44M
Change in working capital -0.69M -1.32M -1.90M 2.20M -0.09M
Stock based compensation 0.68M 1.28M 0.54M 0.25M 0.16M
Other non cash items 0.63M 1.42M 0.45M 0.74M 0.59M
Free cash flow 11.72M 7.73M 6.48M 10.81M 8.68M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
HLN
Haleon PLC
-4.20
1.10%
376.00 20.24 18.94 2.95 2.02 3.68 14.19
HIK
Hikma Pharmaceuticals PLC
4.00
0.24%
1704.00 9.73 9.03 0.85 1.45 1.53 6.07
HCM
HUTCHMED China Ltd
-2.00
0.95%
208.00 5.38 19.30 3.37 2.02 2.25 2.40
AGY
Allergy Therapeutics
-
-%
4.25 - 106.38 11.72 159.47 12.12 -4.15

Profile*

Animalcare Group Plc

Animalcare Group plc develops, sells, and distributes licensed veterinary pharmaceuticals, and services for companion and production animals, and equine veterinary markets. The company has a collaboration with 272Bio Limited to develop and commercialize a novel biological treatment for a common equine skin condition, known as sweet itch. The company operates in Belgium, the Netherlands, the United Kingdom, Germany, Spain, Italy, Portugal, Asia, the Middle East, Africa, European Union, and internationally. Animalcare Group plc is based in York, the United Kingdom.

Moorside, York, United Kingdom, YO32 9LB

44 1904 487 687

201

Name Title Year Born
Ms. Jennifer Ann Julia Winters B.Sc. CEO & Director 1960
Mr. Christopher James Brewster CFO, Company Sec. & Director 1977
Carla De Schepper Group HR Director NA
Mr. Jeroen Bastijns Head of Bus. Devel. NA
Mr. Emilio Gil Ventura Head of Strategy & Country Mang. of Spanish Bus. NA
Stephen Pearson Group Head of Supply Chain NA
Martin Gore Head of Commercial NA
Ms. Jennifer Ann Julia Winter B.Sc. CEO & Director 1960
Mr. Christopher James Brewster CFO, Company Secretary & Director 1976

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…